Share Market Newspaper

Dravet syndrome Therapeutic Pipeline Analysis | Insights into Latest FDA and EMA Approvals, Clinical Trials, and Treatment Algorithm | Biocodex (DIACOMIT), Takeda (Soticlestat), Eisai, Epygenix

 Breaking News
  • No posts were found

Dravet syndrome Therapeutic Pipeline Analysis | Insights into Latest FDA and EMA Approvals, Clinical Trials, and Treatment Algorithm | Biocodex (DIACOMIT), Takeda (Soticlestat), Eisai, Epygenix

September 21
18:34 2022
Dravet syndrome Therapeutic Pipeline Analysis | Insights into Latest FDA and EMA Approvals, Clinical Trials, and Treatment Algorithm | Biocodex (DIACOMIT), Takeda (Soticlestat), Eisai, Epygenix
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Dravet syndrome therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Dravet syndrome Pipeline Insight, 2022″ report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Dravet syndrome Market. 

The Dravet syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Dravet syndrome Pipeline Analysis

Dravet syndrome Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of Dravet syndrome and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dravet syndrome Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Dravet syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

DelveInsight’s Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III),

• Mid-stage products (Phase II)

• Early-stage products (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Latest Clinical and Commercial Developments in the Dravet syndrome Therapeutics Market

Current treatment options are limited, and the constant care required for someone suffering from Dravet syndrome can severely impact the patient’s and the family’s quality of life. Patients with Dravet syndrome face a 15-20% mortality rate due to SUDEP (Sudden Unexpected Death in Epilepsy), prolonged seizures, seizure-related accidents such as drowning, and infections.

To provide effective therapeutics solutions, globally some of the key companies are actively working towards the development of new therapies for Dravet Syndrome. The launch of emerging therapies is expected to transform the treatment dynamics.

On September 21, 2022, Biocodex, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved DIACOMIT for the treatment of seizures associated with Dravet syndrome in patients 6 months and older. The antiseizure treatment, DIACOMIT, first received FDA approval in 2018 for children 2 years and older. With the latest FDA approval, DIACOMIT has become the only FDA-approved medication specifically indicated for Dravet syndrome seizures in children as young as 6 months.

On August 31, 2022, Bright Minds Biosciences reported that it had dosed the first patient in a Phase I trial for its lead product, BMB-101, to treat Dravet Syndrome and other medical indications. The Phase I trial is being conducted in Adelaide, Australia, by CMAX Clinical Research.

Learn How the Ongoing Clinical & Commercial Activities will Affect the Dravet syndrome Therapeutic Segment:

https://www.delveinsight.com/sample-request/dravet-syndrome-pipeline-insight

Dravet syndrome Therapeutics Landscape

There are approx. 15+ key companies which are developing therapies for Dravet Syndrome. Currently, Takeda has its Dravet Syndrome drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Dravet Syndrome Therapeutics Market include:

• Stoke Therapeutics

• Epygenix Therapeutics

• Takeda

• Eisai Inc.

• Virpax Pharmaceuticals

• OPKO Health

• GW Pharmaceuticals

• Xenon Pharmaceuticals

• Biocodex Pharmaceuticals

• Insys Therapeutics, INC

• Ovid Therapeutics

• Novartis

• Thermo Fisher Life Technologies

• Biscayne Pharmaceuticals, Inc.

• Mylan

• Sage Therapeutics, Inc.

• AbbVie Inc

• Johnson & Johnson

• Zogenix

• PTC Therapeutics

• Epygenix Therapeutics

And many more

Dravet Syndrome Emerging Drugs Covered in the report include:

• Soticlestat (Takeda)

• Lorcaserin (Eisai Inc.)

• EPX100 (Epygenix Therapeutics)

• STK-001 (Stoke Therapeutics)

• VRP324 (Virpax Pharmaceuticals)

• AntagoNAT (OPKO Health)

• Diacomit

• Epidiolex

• Ataluren

• Fintepla (fenfluramine)

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

https://www.delveinsight.com/sample-request/dravet-syndrome-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Dravet syndrome Current Treatment Patterns

4. Dravet syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Dravet syndrome Late Stage Products (Phase-III)

7. Dravet syndrome Mid-Stage Products (Phase-II)

8. Dravet syndrome Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Dravet syndrome Discontinued Products

13. Dravet syndrome Product Profiles

14. Key Companies in the Dravet syndrome Market

15. Key Products in the Dravet syndrome Therapeutics Segment

16. Dormant and Discontinued Products

17. Dravet syndrome Unmet Needs

18. Dravet syndrome Future Perspectives

19. Dravet syndrome Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/dravet-syndrome-pipeline-insight

 

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Mucinoses Market

“Mucinoses Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Mucinoses Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/